drugset / Trial / NCT04750759
Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat
RandomizedParallel-groupSingle-blindTreatment
Summary
Niclosamide (2000 mg QD) and Camostate (600 mg QID) are expected to be safe and well-tolerated as a combination therapy and to show clinically beneficial for COVID-19 patients.
Timeline
- Start
- 2021-02-03
- Primary completion
- 2021-10-29
- Completion
- 2021-10-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Camostat | Small molecule | 600 mg | Oral |
| Comparator | Niclosamide | Unknown | 2000 mg | Oral |